Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BI 409306 in Schizophrenia, Alzheimer's, and Healthy Volunteers
NCT02392468Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2015
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of osoresnontrine in schizophrenia and Alzheimer's disease (AD) (6 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage of Participants With Adverse Events (AEs), Coded to the Medical Dictionary for Regulatory Activities - System Organ Class Eye Disorders at 21 days. Started Apr 2015; status: completed.
02
Drugs
osoresnontrine
03
Conditions
schizophreniaAlzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02392468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02392468.